CEL-SCI EXPANDS ITS PHASE I STUDY FOR TREATMENT OF ANAL WARTS IN HIV/HPV CO-INFECTED Print E-mail
Monday, 20 July 2015 18:45
Vienna, VA-- CEL-SCI Corporation (NYSE MKT: CVM) (“CEL SCI” or the “Company”) today announced it has added a second clinical site for its Phase I clinical trial evaluating peri-anal wart immunotherapy in HIV/HPV co-infected men and women with its investigational cancer immunotherapy Multikine* (Leukocyte Interleukin, Injection).
Read more...
 
Actinium Advances Iomab-B Towards Phase 3 with Pre-IND Meeting Request Print E-mail
Wednesday, 15 July 2015 10:49
NEW YORK, NY - July 15, 2015 - Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it has submitted a request for a pre-IND (Investigative New Drug) meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug candidate currently preparing to commence the pivotal Phase 3 trial. 
Read more...
 
With New Spotlight on Batten Disease – Can Gene Therapy Provide an Answer? Print E-mail
Wednesday, 08 July 2015 21:32
Media reports tied to famous faces in Hollywood are shedding new light on the inherited genetic disorder, juvenile Batten disease, a lysosomal storage disease that primarily affects the nervous system in children.
Read more...
 
With New Spotlight on Batten Disease – Can Gene Therapy Provide an Answer? Print E-mail
Wednesday, 08 July 2015 20:15
Featured Expert, Dr. Tammy Kielian, Ph.D Professor Dept. Pathology & Microbiology. U. Nebraska Medical Center
Read more...
 
CEL-SCI REPORTS JUNE PATIENT ENROLLMENT IN ITS PHASE 3 HEAD AND NECK CANCER TRIAL Print E-mail
Wednesday, 01 July 2015 10:25
Vienna, VA--CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that in June it has enrolled 25 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in just diagnosed, not yet treated patients with head and neck cancer.
Read more...
 
Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study Print E-mail
Tuesday, 30 June 2015 09:55
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical Company focused on the development of oral drug delivery systems, announced today that the first patient has been screened in the Company's Phase IIb trial of its oral insulin capsule, ORMD-0801.  
Read more...
 
AAA Signs Distribution Agreement for Lutathera in Japan with FUJIFILM RI Pharma, Co., LTD Print E-mail
Tuesday, 30 June 2015 09:19
Advanced Accelerator Applications S.A. (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), announces that it has entered into a distribution agreement for Lutathera in Japan with FUJIFILM RI Pharma, Co., LTD (“FRI”), a leading in-country distributor of nuclear medicine and diagnostic imaging products. Lutathera is currently in a pivotal Phase III trial, both in the US and EU, with results expected in Q3.
Read more...
 
PharmaCyte Biotech Enters into Research and Consulting Agreements with University of Technology Sydney Print E-mail
Tuesday, 23 June 2015 10:35
SILVER SPRING, MD--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and
diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has signed a major Research Services Agreement and

Error. Page cannot be displayed. Please contact your service provider for more details. (13)

an important Consulting Contract with the University of Technology Sydney (UTS) in Australia.
Read more...
 
PlasmaTech Biopharmaceuticals Announces Name Change to Abeo Print E-mail
Friday, 19 June 2015 08:53
NEW YORK, NY--PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced a name change to Abeona Therapeutics, Inc. to reflect its broader rare disease commitment.
Read more...
 
PlasmaTech Biopharmaceuticals Expands Rare Disease Pipeline With License Agreement for Gene Therapy in Fanconi Anemia & CRISPR/Cas9-Based Technology Platform for Rare Blood Disorders Print E-mail
Monday, 15 June 2015 08:10
NEW YORK, NY and CLEVELAND, OH--PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, announced today that it has added another adeno-associated virus (AAV) gene therapy program to its product pipeline. The Company has licensed an AAV gene therapy and IP from the University of Minnesota to treat patients with Fanconi anemia (FA) disorder and other rare blood diseases.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 2 of 12
BMR:1